EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Real‐World Evidence Assessment of the Risk of Nonfatal Stroke in Patients Prescribed SGLT2 Inhibitors

Alessandra T Ayers iD, Cindy N Ho iD, Umesh Masharani iD, William C Pike iD, Honor Magon iD, Michael L Jackson iD, Saurabh Gombar iD, Agatha F Scheideman iD, Mandy M Shao iD, David C Klonoff iD

Stroke Research and Treatment · 2026-01 · 2026 (1)

DOI: 10.1155/srat/6411721 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Stroke Research and Treatment, online erschienen am 25.06.2026. Verfasst von Alessandra T Ayers und 9 weiteren Autor:innen. Beteiligte Einrichtung: Diabetes Technology Society, Burlingame, California, USA. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Use of sodium‐glucose cotransporter 2 inhibitors (SGLT2i) in adults with Type 2 diabetes (AwT2D) has recently been associated with decreased stroke risk. In this study, we investigate the impact of SGLT2i on stroke. Materials and Methods We conducted a cohort study using an electronic health record (EHR) representing 66 million patients to examine whether AwT2D have a lower incidence of stroke and/or transient ischemic attack (TIA) if treated with SGLT2i. All analyses were completed utilizing high‐dimensional propensity score matching to control for confounders.

Results

AwT2D treated with SGLT2i compared to other antidiabetic medications, assessed after 1 year, starting 2 weeks after the date of prescription of SGLT2i or other antidiabetic drug, had a significantly lower incidence of any stroke (Odds Ratio (OR): 0.84 with 95% Confidence Interval (CI) 0.79–0.91, p < 0.001), hemorrhagic stroke (OR: 0.72 with 95% CI 0.59–0.88, p < 0.001), ischemic stroke (OR: 0.86 with 95% CI 0.77–0.95, p = 0.005), and TIA (OR: 0.87 with 95% CI 0.80–0.95, p = 0.003).

Conclusion

Among AwT2D, those treated with SGLT2i had lower incidence of stroke and TIA compared with adults treated with other antidiabetic medications.

Schlagwörter

Stichwörter der Autor:innen

SGLT2 inhibitorsType 2 diabetescardiovascularhemorrhagic strokeischemic stroke

Autor:innen und Institutionen

  • Diabetes Technology Society, Burlingame, California, USA.
  • University of California San Francisco, San Francisco, California, USA, ucsf.edu.
  • Atropos Health, New York, New York, USA.
  • Stanford University, Stanford School of Medicine, Stanford, California, USA, stanford.edu.
  • Diabetes Research Institute, Mills-Peninsula Medical Center (Sutter Health), San Mateo, California, USA, diabetesresearch.org.

ORCID-Profile: Alessandra T Ayers, Cindy N Ho, Umesh Masharani, William C Pike, Honor Magon, Michael L Jackson, Saurabh Gombar, Agatha F Scheideman, Mandy M Shao, David C Klonoff

Zitieren

APA

Ayers, A. T., Ho, C. N., Masharani, U., Pike, W. C., Magon, H., Jackson, M. L., Gombar, S., Scheideman, A. F., Shao, M. M., & Klonoff, D. C. (2026). Real‐World Evidence Assessment of the Risk of Nonfatal Stroke in Patients Prescribed SGLT2 Inhibitors. Stroke Research and Treatment, 2026(1). https://doi.org/10.1155/srat/6411721

Vancouver

Ayers AT, Ho CN, Masharani U, Pike WC, Magon H, Jackson ML, et al. Real‐World Evidence Assessment of the Risk of Nonfatal Stroke in Patients Prescribed SGLT2 Inhibitors. Stroke Research and Treatment. 2026;2026(1). doi:10.1155/srat/6411721

BibTeX
@article{Ayers2026,
  author = {Ayers, Alessandra T and Ho, Cindy N and Masharani, Umesh and Pike, William C and Magon, Honor and Jackson, Michael L and Gombar, Saurabh and Scheideman, Agatha F and Shao, Mandy M and Klonoff, David C},
  title = {Real‐World Evidence Assessment of the Risk of Nonfatal Stroke in Patients Prescribed SGLT2 Inhibitors},
  journal = {Stroke Research and Treatment},
  year = {2026},
  volume = {2026},
  number = {1},
  doi = {10.1155/srat/6411721}
}
Kostenlos starten →